Background-A characteristic of both clinical and experimental atrial fibrillation (AF) is atrial electric remodeling associated with profound reduction of L-type Ca 2ϩ current and shortening of the action potential duration. The possibility that microRNAs (miRNAs) may be involved in this process has not been tested. Accordingly, we assessed the potential role of miRNAs in regulating experimental AF. Methods and Results-The miRNA transcriptome was analyzed by microarray and verified by real-time reversetranscription polymerase chain reaction with left atrial samples from dogs with AF established by right atrial tachypacing for 8 weeks and from human atrial samples from AF patients with rheumatic heart disease. miR-223, miR-328, and miR-664 were found to be upregulated by Ͼ2 fold, whereas miR-101, miR-320, and miR-499 were downregulated by at least 50%. In particular, miR-328 level was elevated by 3.9-fold in AF dogs and 3.5-fold in AF patients relative to non-AF subjects. Computational prediction identified CACNA1C and CACNB1, which encode cardiac L-type Ca 2ϩ channel ␣1c-and ␤1 subunits, respectively, as potential targets for miR-328. Forced expression of miR-328 through adenovirus infection in canine atrium and transgenic approach in mice recapitulated the phenotypes of AF, exemplified by enhanced AF vulnerability, diminished L-type Ca 2ϩ current, and shortened atrial action potential duration. Normalization of miR-328 level with antagomiR reversed the conditions, and genetic knockdown of endogenous miR-328 dampened AF vulnerability. CACNA1C and CACNB1 as the cognate target genes for miR-328 were confirmed by Western blot and luciferase activity assay showing the reciprocal relationship between the levels of miR-328 and L-type Ca 2ϩ channel protein subunits. Conclusions-miR-328 contributes to the adverse atrial electric remodeling in AF through targeting L-type Ca 2ϩ channel genes. The study therefore uncovered a novel molecular mechanism for AF and indicated miR-328 as a potential therapeutic target for AF. (Circulation. 2010;122:2378-2387.)
A trial fibrillation (AF) is a highly prevalent condition associated with pronounced morbidity, mortality, and socioeconomic burden, accounting for more hospitalization days than any other arrhythmias. It can cause or exacerbate heart failure and is a potent risk factor for ischemic stroke resulting from thromboembolism. [1] [2] [3] [4] [5] A characteristic of both clinical and experimental AF is the alteration of electrophysiology that promotes persistent AF even in the absence of progressive underlying heart disease, so-called atrial remodeling or "AF begets AF." [1] [2] [3] This remodeling process is associated with a profound reduction of L-type Ca 2ϩ current (I CaL ) density and shortening of atrial action potential duration (APD), 6 -14 an adaptation mechanism to avoid Ca 2ϩ overload to minimize the threat to cell viability in response to increased firing rate during AF. However, this adaptation, while providing protective negative feedback on Ca 2ϩ loading, is at the cost of generating positive feedback on AF vulnerability. Indeed, it has been shown that ␣ 1D (an ␣ subunit of atrial L-type Ca 2ϩ channel) knockout mice had atrial ECG abnormalities and enhanced AF vulnerability. 15 Although expression deregulation of Ca 2ϩ channel-encoding genes in AF has been documented, the molecular determinants have remained incompletely understood.
Clinical Perspective on p 2387
With the recent surge of research into microRNAs (miRNAs), this category of endogenous noncoding small RNAs has emerged as one of the central players in gene expression regulation, participating in many essential biological processes. 16 -19 The implications of miRNAs in the pathological process of the cardiovascular system have also been recently appreciated. 20 -24 In particular relevance to this study, miRNAs have been documented to play critical roles in regulating cardiac excitability and the associated arrhythmogenicity in a number of pathological settings, including acute myocardial infarction, cardiac hypertrophy, and diabetic cardiomyopathy, through targeting the pertinent genes encoding ion channels and Ca 2ϩ handling proteins. 24 -32 It is quite plausible that miRNAs may also be involved in AF and the associated atrial electric remodeling process. In this regard, 2 recent studies have begun to look into the notion. Girmatsion and colleagues 33 evaluated changes in miR-1 and Kir2.1 subunit expression in relation to I K1 alterations in the left atrium (LA) of patients with persistent AF. miR-1 level was found to be significantly reduced in AF, along with increases in Kir2.1 protein expression and I K1 density. These authors did not provide further insight into delineating the targeting mechanism and the potential role of miR-1 downregulation in AF initiation and maintenance, but on the basis of our previously established relationship between miR-1 and Kir2.1, 24 they proposed a primary role of miR-1 downregulation in I K1 upregulation in AF. Another study from our laboratory suggested an indirect role of miR-133 and miR-590 in smoking/nicotine-induced AF via promoting atrial fibrosis on their expression downregulation. 34 Although these studies provided promising evidence in support of the role of miRNAs in AF, mechanistic data on these small molecules in AF and the associated atrial remodeling in animal models with minimal confounding factors in conjunction with human samples are still missing. The present study was designed to shed light on this issue.
Methods

Induction of AF in Wild-Type Mice
Wild-type (WT) C57BL/6 mice were divided into 2 groups: a control (nϭ14) group and an antagomiR-328 (nϭ10) group. Intracardiac pacing was performed in these animals by inserting an 8-electrode catheter (1.1F, octapolar EP catheter, Scisense, London, Ontario, Canada) through the jugular vein and advancing it into the right atrium and ventricle. 35, 36 Inducibility of atrial arrhythmias was tested by applying 6-second bursts through the catheter electrodes using the automated stimulator that was part of the data acquisition system. The first 6-second burst had a cycle length of 40 milliseconds, decreasing in each successive burst with a 2-millisecond decrement down to a cycle length of 20 milliseconds. Then, 50 g/kg carbachol was injected through the jugular vein. Two minutes later, the same combination of bursts was applied to the animals. Successful induction of AF was defined as a period of rapid irregular atrial rhythm lasting at least 1 second.
Construction of Adenovirus and Infection
The procedures were similar to the study reported by van Rooij et al. 21 Rno-miR-328 precursor DNA (5Ј-GGATCCgACCCCGTCCCCCC-GTCCTCCCCGAGTCCCTCTTTCGTAGATGTCGGGGACCGGGAGAGACGGGAAGGCAGGGGACAGGGGTTTAttttttAAGCTT-3Ј) was synthesized by GenScript (Nanjing, PR China). The fragment was first inserted into adenovirus shuttle plasmid pDC316-EGFP-U6 (Microbix Biosystems Inc, Canada). pDC316-EGFP-U6 was then cotransfected with the infectious adenovirus genomic plasmid pBHGlox⌬E1,3Cre into 293 cells by liposome reagent. After cotransfection of these 2 DNAs, homologous recombination occurred to generate a recombinant adenovirus in which the transgene (precursor miR-328 [premiR-328] ) is incorporated into the viral genome, replacing the ⌬E1 region 37 ( Figure I in the online-only Data Supplement). Mismatched miR-328 was generated by substituting 6 nts within the seed motif as indicated by italics (5Ј-GGATCCgACCCCGTCCCC-CCGTCCTCCCCGAGTCCCTCTTTCGTAGATGTCGGGGGTTGAACGAGACGGGAAGGCAGGGGACAGGGGTTTAttttttAAGCTT-3Ј).
Generation of miR-328 Transgenic Mice
A fragment (320 bp) containing premiR-328 sequence was polymerase chain reaction (PCR) amplified from the mouse genomic DNA (accession No. NT 078575). The fragment was then subcloned into the SalI and HindIII sites of the Bluescript vector (Promega, Madison, Wis) carrying the cardiac-specific ␣-myosin heavy chain (␣MHC) promoter and human growth hormone poly(A) ϩ signal ( Figure III in the online-only Data Supplement). 38 The plasmid was digested at the SpeI site to release the premiR-328 sequence flanked by 5Ј end ␣MHC promoter and 3Ј end poly(A). The fragment was separated on an agarose gel and purified by QIAEX II gel extraction kit (Qiagen No. C 04539, Valencia, Calif). The DNA sample was prepared at a concentration of 3 ng/L ready for injection. A transgenic (Tg) mouse line carrying a mismatched premiR-328 sequence as indicated above was also generated for negative control experiments.
Sexually immature female mice (4 to 5 weeks of age) were superovulated by consecutive PMS and HCG hormone injections to obtain sufficient quantity of eggs (Ͼ250) for injection. These female mice were mated with stud males immediately after the HCG injection. Eggs were harvested the next day from the ampulla of the oviduct of the mated females and treated with hyaluronidase to remove nurse cells. Fertilized eggs were then stored in M16 media (37°C, 5% CO 2 ) until injection. Each egg was individually microinjected with the DNA fragment, and the eggs that did not survive injection were removed. Pseudopregnant female mice were prepared by mating with the vasectomized males. On the day of microinjection, the pseudopregnant females were anesthetized with 0.5% pentobarbital (20 mL/kg). The injected eggs were then implanted into a group of 10 to 15 bilaterally into the oviduct of these animals. The animals were allowed to recover from anesthesia on a warming plate and then returned to the animal room. They were kept under sterile conditions throughout their pregnancy.
The genomic DNA was prepared from tail tissue of the Tg mice and subjected to PCR verification for the presence of miR-328 transgene. The forward primer was designed to recognize ␣MHC (position 5250 to 5268), 5Ј-CCTTACCCCACATAGACCT-3Ј, and the reverse primer was for miR-328 (position 57 to 39), 5Ј-CTGTAGA-TACTTTCTCCCT-3Ј. The PCR profiling was composed of an initial denaturing step at 94°C for 2 minutes and 35 cycles of 94°C for 20 seconds, 60°C for 7 seconds, and 72°C for 20 seconds, followed by a final extension step at 72°C for 5 minutes.
Generation of miR-328 Sponge Tg Mice
A fragment containing 6 antimiR-328 antisense units (5Ј-gtcgacacggaagggcctc-agggccagaattacggaagggcctc-agggccagaattacggaagggcctcagggccagaattacggaagggcctc-agggccagaattacggaagggcctc-agggccagaattacggaagggcctc-agggccagaagctt-3Ј) was synthesized by Shanghai Biological Engineering Inc. The fragment was then subcloned into the SalI and HindIII sites of Bluescript vector (Promega) carrying the cardiacspecific ␣MHC promoter and human growth hormone poly(A)ϩ signal.
The same procedures described above for miR-328 were followed. 38 Knockdown of endogenous miR-328 in F0 was verified, and the 2-month-old Tg mice were used in the experimental studies.
Data Analysis
Group data are expressed as meanϮSEM. Statistical comparisons among multiple groups were performed by ANOVA. If significant effects were indicated by ANOVA, a t test with Bonferroni correction for microarray data or a Dunnett test for patch-clamp data was used to evaluate the significance of differences between individual means. Otherwise, baseline and drug data were compared by paired Student t test, and age-matched comparisons between control and treatment were done by unpaired Student t test. Group comparisons for AF incidence were performed with the 2 test. A 2-tailed PϽ0.05 was taken to indicate a statistically significant difference. Linear and nonlinear least squares curve fitting was performed with CLAMPFIT in pCLAMP 8.0 or GraphPad Prism 4.0. More information on materials and methods is provided in the online-only Data Supplement.
Results miRNA Expression Profile in a Canine Model of AF Induced by Atrial Tachypacing
As an initial step to examine our hypothesis that miRNAs are involved in AF, we used a canine model of AF by atrial tachypacing (A-TP) for 8 weeks to create AF-induced remodeling. 3, 4, 21, 39 As illustrated in Figure 1 A, A-TP increased the vulnerability to AF as indicated by the facilitated induction of AF by electric stimuli and prolonged duration of electrically induced AF. As in previous studies, the cellular and ionic alterations were also consistent with the atrial remodeling process during AF: APD was markedly shortened and APD accommodation (use-dependent shortening of APD) was lost ( Figure 1B ). These electrophysiological abnormalities were presumably caused by reduction of I CaL density ( Figure 1C ). [1] [2] [3] [4] We then conducted expression profiling to identify deregulated miRNAs in the atrial tissues of this canine model of AF using miRNA microarray analysis comparing the differential expressions of miRNAs between control and AF dogs. Four miRNAs-miR-223, miR-328, miR-664, and miR-517-were found to be increased by Ͼ2 fold, and 6 -miR-101, miR-133, miR-145, miR-320, miR-373, and miR-499 -were decreased by at least 50% ( Figure 2A ). Real-time quantitative reversetranscription PCR (RT-PCR) analysis confirmed the significant upregulation of miR-223, miR-328, and miR-664 (miR-517 was undetectable) and the significant downregulation of miR-101, miR-320, and miR-499 ( Figure 2B ). In particular, miR-328 demonstrated the most pronounced change among all, being elevated by 4 times in AF over control. Furthermore, by computational prediction of target genes, we identified 2 genes, CACNA1C and CACNB1, encoding the cardiac L-type Ca 2ϩ channel ␣1c-and ␤1 subunits, respectively, as potential targets for miR-328, an intergenic monocistronic gene located in human chromosome 16. The expression of endogenous miR-328 in heart and the upregulation of miR-328 were verified with Northern blot analysis ( Figure 2C ). These findings prompted us to focus on exploring the role of miR-328 in AF and the associated atrial remodeling.
We first verified the upregulation of miR-328 in the atrial tissue from AF patients with rheumatic heart disease. The miR-328 level was 3.5-times higher in AF patients than in non-AF patients ( Figure 2D and Table I in the online-only 
Forced Expression of miR-328 Recapitulates the Phenotypes of AF and Atrial Electric Remodeling
On the basis of the above findings, we decided to examine whether forced expression of miR-328 is able to recapitulate the phenotypes of experimental AF by taking 2 different approaches. In the first approach, we constructed adenovirus vector carrying the premiR-328 sequence ( Figure I in the online-only Data Supplement) and then performed in vivo gene transfer procedures through direct intramuscular injection of the construct into multiple sites (10 sites within 1 cm in diameter) in the right atrial free wall of healthy dogs. This infection procedure resulted in significant overexpression of miR-328 in the tissue mass 12 hours after injection; the miR-328 level was 4.9-fold higher than in the tissues injected with premiR-328 -free adenovirus vector (Adv-pDC316) ( Figure II in the online-only Data Supplement). This forced expression of miR-328 clearly increased the vulnerability of canine to electric induction of AF with marked prolonged AF duration ( Figure 3A) . Notably, the AF maintenance by miR-328 was significantly attenuated when the antimiR-328 antisense inhibitor oligonucleotide (AMO-328) was coinjected with adenovirus vector carrying premiR-328 (AdvpremiR-328), as indicated by the shortened AF duration ( Figure 3A) .
In the second approach, we developed a premiR-328 transgene (miR-328/Tg) mouse model carrying the cardiacspecific ␣MHC promoter in mice ( Figure III in the onlineonly Data Supplement). Heterozygous litters had remarkably increased miR-328 level (by 11.5Ϯ1.3 times) relative to WT mice. As expected, all 55 miR-328/Tg mice tested developed spontaneous AF from 28 days after birth, as reflected in the surface ECG by the loss of P wave (atrial activation signal) and the appearance of irregular ventricular responses to the abnormal atrial firing ( Figure 3B ), which was otherwise absent in WT littermates. The AF duration, expressed as the percentage of time with AF over the total length of time for ECG recordings (120 minutes), increased with increasing miR-328 level in Tg mice ( Figure IV in the online-only Data Supplement), indicating a "dose-response" relationship between AF phenotype and miR-328 level. Moreover, this transgene model recapitulated the AF remodeling properties. As depicted in Figure 3C , atrial APD was markedly shortened, APD accommodation was abolished, and I CaL density was substantially decreased (Figure 3D ), typical of atrial tachycardia remodeling seen in experimental and clinical AF. [1] [2] [3] [4] Noticeably, these changes were all reversed by the antisense oligo-miR-328 (AMO-328; Figure 3C Figure 3E and 3F). AntagomiR has been documented by numerous studies to be highly effective in knocking down target miRNA with long-lasting efficacy under in vivo conditions. 40 
Loss of Function of miR-328 Reduces AF Vulnerability
We reasoned that if overexpression of miR-328 promotes AF, then downregulation of this miRNA of endogenous origin should prevent AF. To test this hypothesis, we used 2 miR-328 loss-of-function approaches. In the first approach, we generated an miR-328 antisense Tg mouse line (AMO/Tg) to genetically knock down endogenous miR-328. 41 In the second approach, we injected antagomiR-328 into WT mice to knock down the miR-328 of endogenous origin. The animals were all pretreated with low-dose carbachol through the tail vein for 7 consecutive days before attempts were made to induce AF by intracardiac pacing. 35, 36 These treatments facilitated induction of AF ( Figure 4A and 4B) , upregulated miR-328 ( Figure 4C ), and decreased I CaL ( Figure  VI in the online-only Data Supplement). As expected, the AF induction was substantially dampened in both antagomiR-328 -treated WT mice ( Figure 4A ) and AMO/Tg mice (Figure 4B) , as indicated by the reduced number of animals with successful induction of AF by electric stimulation, and shortened AF duration once induced compared with that in Table I in the online-only Data Supplement) compared with non-AF subjects. As negative controls, miR-1, miR-133, and miR-214 were unaltered in AF patients.
the sham-operated, age-matched mice. Quantitative RT-PCR confirmed the downregulation of miR-328 expression; in AMO-Tg mice, the miR-328 level was only 40% of the control value of the WT littermates ( Figure 4C ), and antagomiR-328 reduced the endogenous miR-328 level by Ϸ80% in WT mice relative to the animals treated with mismatched antagomiR.
Correspondingly, the Cav1.2 and Cav␤1 protein levels were reciprocally increased by Ϸ2-fold in AMO/Tg mice ( Figure 4D ) and in WT mice treated with antagomiR-328 ( Figure VI in the online-only Data Supplement). These above changes were not observed in the WT mice treated with mismatched antagomiR-328 or in the mismatched AMO/Tg mice. We also performed additional experiments to exclude the possible contribution of structural components to the ability of miR-328 to induce AF ( Figure VII in the onlineonly Data Supplement).
CACNA1C and CACNB1 Genes as Targets for miR-328
Having established that gain of function of miR-328 promotes while loss of function of miR-328 abrogates AF, we went on to delineate the target genes of miR-328 that play a key role in AF and the associated electric remodeling process. As mentioned, our computational analysis pointed to a possibility of miR-328 regulating CACNA1C and CACNB1 genes because they contain in their 3Ј untranslated regions and coding regions multiple sequence motifs complementary to the "seed site" of miR-328 ( Figure VIII in the online-only Data Supplement). To experimentally establish these 2 genes as cognate targets of miR-328, we engineered the fragments containing the binding sites for miR-328 in these candidate target genes into the 3Ј untranslated region of the luciferase gene and carried out luciferase reporter activity assays. As illustrated in Figure 5A , transfection of miR-328 (10 nmol/L) with the luciferase expression constructs carrying each of the target fragments caused a substantial reduction of luciferase activities. The decreases were efficiently reversed by AMO-328 (10 nmol/L). Furthermore, a negative control construct did not affect the luciferase activities.
The ability of miR-328 to repress the expression of these genes was further verified by Western blot analysis of the levels of the proteins encoded by their corresponding mRNAs in neonatal rat atrial myocytes transfected with miR-328 ( Figure 5B ). This downregulation was efficiently prevented by AMO-328. The efficacy of AMO-328 to knock down the mature miR-328 in all our experimental settings was confirmed ( Figure II in the online-only Data Supplement).
In line with the above data, the protein levels of Cav1.2 and Cav␤1 were found to be significantly reduced in the atrial tissues of A-TP dogs ( Figure 5C ). As a negative control, an unrelated protein connexin43 was also analyzed, and no change was found between A-TP and control dogs. Similar downregulation of Cav1.2 and Cav␤1 protein levels was consistently observed in miR-328/Tg mice ( Figure 5D ). Effects of miR-328 on the transcript level of CACNA1C and CACNB1 were also evaluated in miR-328/Tg mice and in cultured neonatal rat atrial myocytes. miR-328 induced Ϸ30% decreases in CACNA1C and CACNAB1 transcript levels ( Figure 5E ). Significant downregulation of Cav1.2 and Cav␤1 protein levels was also observed in AF patients ( Figure 5F ).
The relative abundances of miR-328 and CACNA1C in the RNA samples from healthy human atrial tissues were quantified by real-time RT-PCR. The results revealed that the copy number of miR-328 is Ϸ4000 in a cardiac cell, some 7-times higher than that of CACNA1C (copy number, Ϸ600), indicating that the endogenous concentration of miR-328 should be sufficiently high to produce posttranscriptional repression of CACNA1C in a cardiac cell ( Figure IX in the online-only Data Supplement). We then further ruled out the possibility that miR-328 acts by targeting ion channels other than CACNA1C and CACNB1 (Figure X in the online-only Data Supplement).
Discussion
Sustained atrial tachycardia as a stress, like clinical AF, can modify atrial properties so that AF recurs and maintains itself more readily; the rapid atrial rate of AF is the primary stimulus of the remodeling process, and such a remodeling has also been called atrial tachycardia remodeling. 1, 2, 42, 43 Atrial tachycardia remodeling is suggested to contribute to a variety of clinically important phenomena, including the tendency of paroxysmal AF to become persistent, the tendency of AF to recur soon after cardioversion, and the tendency for longer-lasting AF to become refractory to pharmacological cardioversion. Experimentally, AF and atrial tachycardia remodeling can readily be induced by A-TP. 3, 4, [37] [38] [39] 42 Intensive studies have been done to understand ionic mechanisms for AF and the associated atrial electric remodeling. It has been widely accepted that for the A-TP-induced electric remodeling, diminished I CaL density resulting from expression downregulation and functional impairment of L-type Ca 2ϩ channel protein is a hallmark and a critical causal factor. In other words, excessive reduction of I CaL predicts enhanced AF vulnerability. In the present study, we found that miR-328 is aberrantly upregulated in dogs with AF induced by A-TP and in patients with AF, and this overexpression is accompanied by reduction of I CaL and shortening of atrial APD. Moreover, gain of function of miR-328 through forced expression facilitates AF and recapitulates the major characteristics of atrial electric remodeling; in sharp contrast, loss of function of miR-328 by genetic knockdown or miRNA interference approaches did the opposite. We further established CACNA1C and CACNB1, which encode I CaL channel ␣1c-and ␤1 subunits, respectively, as cognate target genes for miR-328. The study therefore provides the first detailed characterization of the role of miRNAs in AF and the associated atrial electric remodeling.
A recent study reported by Girmatsion et al 33 showed that the miR-1 level is decreased in AF patients and, in parallel, the inward rectifier K ϩ current I K1 and I K1 channel protein Kir2.1 were increased. It was speculated that downregulation of miR-1 may underlie the upregulation of I K1 , which is another critical factor for AF. Unfortunately, no detailed experimental investigation was conducted in this study to clarify whether downregulation of miR-1 plays a role in AF induction and maintenance and to elucidate whether the cause-effect relationship between the changes of miR-1 and I K1 exists in this particular case. Moreover, Kir2.1 was found to be upregulated by only 1.5 times at the protein level but by 3 times at the mRNA level. 33 These results are inconsistent with the expected effect of miR-1 because miR-1 has been documented not to affect the KCNJ2 (Kir2.1 mRNA) level. 24 Further evidence against the role of miR-1 in AF came from the same study showing that connexin 43, another validated target of miR-1, 24 was found to be unaltered in expression. 33 Furthermore, in the present study, we observed no significant changes of miR-1 level in either the canine model of AF by A-TP or the atrial samples from patients with clinically defined AF. The reason for the discrepancy in miR-1 expression in AF patients between the study by Girmatsion et al 33 and this study remained unclear. Although the patient populations recruited for the 2 studies both had rheumatic heart disease, many confounding factors (eg, degree of heart damage, ethnic groups, age, and gender) may contribute. Consistently in our study, the increase in miR-328 level found in AF dogs was also observed in the AF patients. This fact points to a rationale for using animal models to minimize confounding factors for addressing some clinical questions and dissecting the molecular mechanisms.
Considering the previous studies that identified miR-1 as an arrhythmogenic miRNA, 24, 26, 28, 31 it appears that in addition to the muscle-specific miRNA, ubiquitously distributed miRNAs like miR-328 can have strong arrhythmogenic potential. In addition, it is likely that multiple miRNAs contribute to controlling arrhythmogenicity of the heart and that different miRNAs are involved in different types of arrhythmias under different pathological conditions of the heart. miR-1 has been shown to be critical in ischemic ventricular arrhythmias by slowing cardiac conduction via targeting connexin43 and inward rectifier K ϩ channel. 24 miR-133, another muscle-specific miRNA, may play a role in the abnormal QT prolongation in diabetic cardiomyopathy through repressing KCNH2 encoding human ether-a-gogorelated gene K ϩ channel. 29 The present study revealed, for the first time, the role of miRNA in AF and miR-328 as a new arrhythmogenic miRNA acting on L-type Ca 2ϩ channel subunits. In addition to miR-328, we found that miR-223 and miR-664 were significantly upregulated in AF dogs and patients ( Figure 2B and 2D) . However, miR-223 was predicted not to target any cardiac-expressed ion channel/ transporter genes, and miR-664 is expressed at an extremely low level ( Figure IX in the online-only Data Supplement). These 2 miRNAs could hardly play a significant role in AF and the associated atrial electric remodeling process. Further evidence in support of this notion is the fact that manipulating miR-328 alone, either gain of function or loss of function, is sufficient to alter the propensity of AF accordingly.
Our data also present the first demonstration that miR-328 targets the genes encoding L-type Ca 2ϩ channel proteins to reduce I CaL density and to shorten APD in atrial myocytes, which is likely a mechanism underlying the atrial arrhythmogenic potential of miR-328. In agreement with this notion, Mancarella et al 15 have shown that knockout of ␣ 1D (another ␣ subunit of atrial L-type Ca 2ϩ channel) alone is sufficient to cause atrial ECG abnormalities and to enhance AF vulnerability in the absence of changes of other currents such as I Na , I Ca-T , I K , I f , and I to . Moreover, atrial tachyarrhythmias cause atrial mechanical dysfunction related to abnormal handling of cellular Ca 2ϩ , which contributes to thrombus formation. Our findings that miR-328 represses L-type Ca 2ϩ channel proteins may also explain the impaired atrial contraction during AF because I CaL is known to be crucial for excitation-contraction coupling, and reduction of I CaL could well lead to weakening of cardiac contraction. 1, 2 Finally, the ability of the antagomiR-328 to rescue miR-328/Tg mice from the AF phenotype and the associated atrial remodeling properties suggests the potential of miR-328 as a target for molecular conversion of AF to sinus rhythm. Normalization of the miR-328 level to the normal range may well be a novel strategy for converting AF to sinus rhythm in the clinical setting. In this sense, antagomiR approach appears to represent a wise choice, for this technique has been reported to have superior cellular stability and miRNA specificity under in vivo conditions. 40 It should be noted that although our study identified miR-328 as an important factor in controlling experimental AF, it does not exclude other mechanisms for determining AF, and our findings in experimental models may not be applied directly to human AF. Nonetheless, our study does provide novel insight into experimental AF and a new aspect of the role of miRNAs in cardiac disease. Moreover, we are well aware of other limitations in our study. First, although downregulation of I CaL has been commonly accepted as a key event causing AF and atrial electric remodeling, our study did not give provide evidence for the downregulation of I CaL to mediate AF occurring with miR-328 overexpression. The second limitation of our study is that atrial electric remodeling properties are different among different types of underlying heart disease. Our findings obtained from AF induced by A-TP should not be extrapolated to other types of AF. For example, the electric remodeling in AF occurring in failing heart has different properties and ionic mechanisms: Atrial APD is not shortened and I CaL may not be reduced. Although miR-328 is involved in tachyarrhythmic AF, whether it also plays a role in AF of other causes is unclear.
It is worth mentioning that miR-328 has been implicated in many other pathological conditions. For example, miR-328 is thought to play a role in Alzheimer disease by regulating the ␤-amyloid precursor protein-converting enzyme, 44 in the malignant progression of gliomas, 45 in primary biliary cirrhosis, 46 in the expression of breast cancer resistance protein, 47 and in chronic bladder pain syndrome. 48 These findings indicate the widespread pathophysiological function of miR-328 in humans. Moreover, in all these cases, abnormal upregulation of miR-328 is a common finding; therefore, knockdown of miR-328 expression may be a useful strategy for many diseases associated with miR-328. 
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